Part 1. Overview Information

Key Dates

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide,except where instructed to do otherwise (in this FOA or in a Notice from NIH Guide for Grants and Contracts ).

Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Background

Protecting the public from environmental health risks requires both the generation of science-based information about exposure occurrences and exposure-health relationships, as well as the translation of such information into actions to reduce or eliminate exposure, prevent disease, and promote health. The distinctive needs of individual communities are key for identifying environmental health problems and devising appropriate disease and exposure prevention or remediation tactics. Furthermore, by fostering community-researcher partnerships, vital information that has been identified by the community about exposures and disease prevalence can be used by the researchers to identify the linkages between such exposures and disease and to develop preventive strategies to promote health and reduce risk of disease across the populations at highest risk. Placing an emphasis on equitable partnerships between community and researcher in environmental public health research also ensures that:

• Communities will have a role in identifying and defining problems and risks related to environmental exposures and stressors that are of greatest importance to them.
• Communities will receive the scientific and financial support necessary to conduct high quality research in partnership with investigators that will accurately characterize the distributions and sources of environmental exposures and exposure-health relationships in their community and empower all involved to take action to reduce potential health risks.
• Communities will actively participate with researchers and public health professionals in developing effective strategies for training/education, communication, remediation and prevention in response to environmental threats in order to reduce or eliminate such exposures and to improve health outcomes.
• Communities will ensure that strategies and education are provided in accessible, culturally appropriate formats and developed at a literacy level and in language(s) appropriate for members of that community.

Community engagement (CE) lies on a continuum that reflects the level of involvement of community members, or representatives of specific subpopulations, in the research. The continuum of involvement ranges from community consent to research to full participation and shared leadership of community members in the research design and implementation. Community based participatory research (CBPR) is a recognized approach of Community Engaged Research (CEnR).

For the purpose of this FOA, CEnR is defined as the full participation of community members in the identification of exposures of concern to that community, suitable cohorts and the specific needs of subpopulations; the development of the research questions and research design; the translation and dissemination of study results; the development and implementation of an environmental action plan; and the development of methods for evaluating the success of the project. In addition, for the purpose of this FOA, CEnR should entail the involvement of sufficient numbers of individuals and community-based organizations to adequately represent all segments of their community. By the involvement of larger numbers of community members, CEnR can more effectively reflect the diversity of community values, create an inclusive environment for all affected stakeholders, nurture collaboration, build community capacity to sustain interventions and implementation plans, and increase health and environmental literacy among those involved.

CEnR is particularly vital in addressing environmental justice issues. Environmental justice refers to the need to remedy the unequal burden of exposure and disease borne by socioeconomically disadvantaged persons (e.g. populations defined as minority, low income, or American Indian/Alaska Native tribes). Geographic location and socioeconomic status play important roles in environmental exposure of these sub-populations as does multigenerational exposures. In addition, the lack of resources for early identification of the effects of toxic agents, or the means to address known exposures, may lead to an increased disease burden among people who are economically least able to cope with it. Research to identify and characterize environmental exposures that disproportionately burden these sub-populations can lead to public health action that will reduce the associated health disparities. Furthermore, active participation of community members in the formulation of environmental health research questions and in the conduct and translation of research findings can help community members better understand the associated health risks and empower them to make informed decisions or to initiate local activities to prevent ongoing chronic and/or cumulative exposures that disproportionately affect them.

Objectives and Scope

Since 2009, the NIEHS has invited applications for the Research to Action program to bring together environmental health researchers and community members to assess and address environmental public health issues of greatest concern to their communities. This program is a key component of the PEPH network, that encompasses a variety of research, communication, and training/educational activities to identify, prevent, reduce, or eliminate environmental exposures that lead to adverse health outcomes in communities. PEPH meetings involve grantees from many NIEHS programs, including Research to Action, and allow opportunities for networking, interaction and collaboration across programs.Currently funded projects are addressing a variety of environmental health issues and include a diverse set of communities. A description of currently funded grants under the Research to Action program can be found at: https://www.niehs.nih.gov/research/supported/translational/peph/prog/rta/index.cfm.

This FOA intends to expand the number and scope of projects supported through the NIEHS Research to Action program. The two main objectives of this initiative, however, remain the same: 1) to conduct multi-disciplinary research to collect and characterize information about environmental health concerns of significance to a community and 2) to develop and implement a strategy to translate and disseminate research findings to community members, public health professionals and/or policymakers to support an action that will ultimately promote the reduction of exposure(s) and reduce the health impact from environmental stressors.

To meet these stated objectives, applicants should propose CEnR projects that incorporate three elements - research, community engagement and public health action. A third, optional element is evaluation. These three elements are discussed further below.

Community-engagement

All projects should include, at a minimum, one health researcher with a background in environmental health research and community partners (such as member(s) of affected communities and/or representatives of community-based organization(s) (CBOs). CBOs relevant to this announcement include community and neighborhood organizations; youth, elder or faith-based organizations; disease advocacy organizations; Citizen Science groups; and/or educators. Additional organizations who would be relevant research partners in addition to the community partner include local or state public health departments and laboratories, and regional or national organizations whose mission is to address environmental risks to health.

Project teams are also encouraged that incorporate expertise in social science, evaluative methods, and communications and be comprised of, and co-developed by, researchers and community members. The projects developed by these partners should be focused on environmental agents or diseases that have been identified by the community as potential or existing public health issues.

Because participation of the affected community is essential for both the identification of environmental health risks to be studied and formulation of research and translation plans, it is expected that fully incorporating equitable input from both researchers and community members is a priority throughout the entire research process. Furthermore, the partnership between the researcher and community partners should appropriately draw upon the unique strengths that each brings to the partnership.

For purposes of this FOA, community refers to populations and groups affected by, or with a shared interest in, environmental exposures and related health outcomes. Populations may be defined by socioeconomic status, geography, exposure(s), race, ethnicity, gender, age, occupation, religion, sexual orientation, disability, illness, or other health condition. The term community-based organization (CBO) is broadly defined. The CBO does not need to be a formally recognized organization, such as a non-profit organization, but should be an established community group(s) or network(s) with a common interest in a particular environmental health concern and that includes representatives of the community . Of note, the involvement of more than one CBO may be necessary to represent the interests and concerns of all members of the community (for example, the distinct needs of different age groups or diseases, the cultural constraints related to a particular ethnic or religious sub-population.)

Responsibilities of the research partner and community partner include, but are not limited to, collaborating on (a) determining what information and research questions the proposed study can and cannot provide and address, (b) identifying the most appropriate research design and methodology, (c) ensuring research findings are translated effectively into public health action, and (d) helping translate and communicate study findings to community members in appropriate and accessible formats.

Given the advanced scope of the NIH R01 mechanism used for this FOA, it is anticipated the community-research partnerships will already be established and that applicants will be able to demonstrate evidence of successful past collaboration such as preliminary data from previous research in the community. Capacity building activities to develop training and educational programs, or to establish a new community-researcher partnership, would not be considered appropriate for this FOA.

Research Element

The objective of this element is to support research that will increase knowledge of how environmental exposures impact health and disease in communities. This can include descriptive studies intended to increase understanding of exposure levels, sources or prevalence of exposure-related health conditions among the community, or hypothesis-driven studies designed to improve understanding of the exposure-health outcome relationship. All studies must be motivated by the expressed concerns of a community and the need for scientifically-based information to develop or test the environmental public health action element of the project. The research element of projects may include descriptive research to fill research gaps by characterizing sources of exposures, measure exposure levels, or the prevalence of exposure-related health conditions among members of the community and the community itself, as well as hypothesis-driven studies designed to improve understanding of the exposure-health outcome relationship. A key requirement is that research findings should be used to directly inform a public health implementation action plan. Furthermore, while it is anticipated that research will entail primary data collection, projects should build upon previous research conducted with the community and existing findings, and may also take advantage of existing data sources if such resources can adequately address the research question(s) co-developed by the researcher-community partnership team and produce the new information needed for a public health action plan. Projects are encouraged that include methodologies for integrating local knowledge about the environment or locally gathered data, such as Tribal Ecological Knowledge approaches and/or citizen science efforts, along with traditional research approaches.

For purposes of this FOA, environmental exposure is broadly defined and can include a variety of environmental contaminants. This does not include exposures to infectious diseases, poorly built or maintained housing, or other aspects of the built environment related solely to social conditions (e.g, poverty, food deserts, density, noise and/or violence). Instead, projects should focus on environmental exposures that meet all the following criteria:

• The exposure(s) is considered a significant environmental health issue of concern to the community.
• The exposure(s) is suspected to be associated with a health effect that has a large public health burden, disproportionately impacts the community of interest (such as environmental justice issues) and/or is an emerging or re-emerging environmental agent(s) with potential widespread exposure.
• The researcher and community are lacking information needed to support the proposed public health action, such as data on exposure levels, sources, or potential health effects.

The type of research study proposed should be motivated by existing needs identified by the community and lead to an environmental public health implementation action plan. Specific examples of research topics that are of interest for this FOA include, but are not limited to:

• The cumulative health impact of exposure to multiple environmental stressors on health risks (e.g., the cumulative health effects of exposure to multiple endocrine disruptors; the combined effect/interaction between physical, social, and neighborhood-level environmental stressors; interactive effects of genetics, diet, and environmental exposures on health).
• The burden on human health from hazardous pollutants or health conditions associated with a known toxic waste site, nuclear facility, chemical plant, or resource extraction site (e.g., mine or hydraulic fracturing site) where, for example, a new school, housing development, or community center is to be built.
• Exposure to mixtures of toxic substances and associated health impacts among populations that may experience higher exposure or particular sensitivity to exposure (e.g., emergency response personnel exposed to disaster recovery or mitigation sites).
• The impact of extreme weather on particularly vulnerable communities or populations (e.g., those living in coastal or flood prone communities, tribal communities, the elderly, and children).

Applications that consider interactions between environmental contaminant exposures and the social or physical environment or infectious diseases (as a potential modifier of the health risk associated with exposure to an environmental chemical) are encouraged. However, applications that focus on the social/physical environment or infectious disease alone will not be considered responsive to this initiative.

Public Health Action Element

For the purposes of this FOA, public health action includes campaigns, programs, interventions, and policies intended to elicit a change in behavior or practice that will lead to the reduction or elimination of exposures, the prevention of disease and disability and to promote the health of a population. Public health action may be targeted at the individual, neighborhood, or community level, or developed as models that have national public health practice application. Participation of the affected community in identifying the most effective public health action plan is essential.

The environmental public health action element may include a variety of educational, communication, prevention, or behavioral change activities. This element should be evidence-based, incorporating knowledge gained through the research element of the project, and targeted towards supporting change that will improve the health of a community, reduce or eliminate the exposure, or decrease the prevalence of local exposure-related health conditions. Additionally, each project team is encouraged to implement an evaluation of project processes and, when possible, outcomes. The evaluation element could provide systematic information that can be used to strengthen the project over its life cycle and to assess the effectiveness and impact of the project.

Examples of environmental public health action include, but are not limited to:

• Campaigns to change individuals behaviors that will lead to exposure reduction.
• Educational programs for community health care providers about the health risks associated with a prevalent environmental exposure in their community.
• Innovative application of social media and other mobile technologies to promote bi-directional communications with community partners and to effectively communicate findings to all segments of affected populations.
• Local, regional, or national strategies to raise policymaker awareness of the link between environmental/occupational exposures and adverse health outcomes or to test the effectiveness of a particular intervention.
• Local, state or tribal programs that address management of symptoms related to populations with ongoing and/or multiple exposures.
• Collaborations with public health departments and laboratories to develop and implement evidence-based communications about recognizing, mitigating or preventing local environmental risks.
• Community programs that focus on health promotion and disease prevention related to health risks in environmental exposures.
• Community programs that enhance the quality of life in individuals with chronic disease related to environmental exposures.

Applicants should develop strategies that translate the findings from the research element of the study to action. The strategy should be designed to help support or promote action that will result in the prevention or reduction of exposure among community members at the local, regional or national level, ultimately leading to improved health outcomes and quality of life. Examples of possible public health action strategies include, but are not limited to:

• Develop and implement community-based, culturally appropriate communication and outreach programs to educate community members about potential sources of exposure, the potential associated health risks, and how they might reduce their exposure.
• Develop and implement exposure reduction or prevention strategies.
• Develop informational materials and risk communication strategies to educate policymakers about potential sources of exposure and the associated potential health risks and economic burden resulting from such exposures.
• Establish and implement community-based training to increase environmental health literacy, and/or health promotion
• Develop targeted community-based training for local policymakers, disaster and emergency response personnel, and for specific segments of the affected community (e.g., trainings developed for implementation by local educators for K-12 students).
• Develop and implement medical and continuing medical education training modules in conjunction with local providers to improve awareness and environmental health literacy among health care and public health professionals on the role of the environmental exposure in disease etiology or exacerbation. Education modules may be developed or adapted to address the specific educational needs of nurses, occupational therapists, lay community health workers, and other health care specialties.

Evaluation Element

Evaluations help community-research partners assess the effectiveness and impact of their projects as well as the factors that led to program success (or failure). In addition, evaluations can supply ongoing, systematic information that strengthens projects during their life cycle. Evaluations should be designed to reflect program goals and objectives.

The NIEHS PEPH program has developed an Evaluation Metrics Manual to serve as a resource for applicants in developing and implementing an evaluation plan for environmental public health research projects. The complete Evaluation Metrics Manual can be accessed electronically at: http://www.niehs.nih.gov/pephmetrics. Key areas addressed in the Manual include community-research partnerships, the translation and dissemination of messages based on research findings, education and training, and capacity building. Applicants are encouraged to review the Evaluation Metrics Manual for guidance on development of an evaluation plan or to include evaluation scientific expertise on the study team.

Examples of potential measures for evaluating the project's processes (activities and outputs) may include:

• Number, type, and/or location of interactions among various partners in the project.
• Number, cost, content, and/or level of community involvement in development and dissemination of education and training information.
• Number of people (community members, researchers, and health care providers) trained to use a specific approach or tool).
• Examples of potential measures for evaluating the project's outcomes may include:
• Proportion of participants reporting attitudinal changes based on the usefulness of materials developed, increases in awareness, knowledge and behavior related to environmental exposure examined by the project.
• Proportion of participants reporting lower exposure to hazardous contaminant targeted by the program.
• The number of local or regional policies or public health practices that were informed by the project’s efforts.

Applicants are encouraged to involve social scientists in the development of these quantitative and qualitative tools to assess progress and programmatic achievements. Applicants are encouraged to implement evaluation during any and all phases of the study. The development and use of a project logic model(s) are also encouraged for evaluation planning (see the Evaluation Metrics Manual, Chapter 7 at http://www.niehs.nih.gov/research/supported/assets/docs/a_c/peph_evaluation_metrics_manual_11513_508.pdf for more information on logic models). In addition to the PEPH Evaluation Metrics Manual, applicants may wish to use the Environmental Health Translational Research Framework to describe how their research will address research gaps and inform practice. The Translational Research Framework and supporting resources can be found online. (https://www.niehs.nih.gov/research/programs/translational/framework-details/index.cfm)

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

Section III. Eligibility Information

1. Eligible Applicants

Higher Education Institutions

• Public/State Controlled Institutions of Higher Education
• Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

• Hispanic-serving Institutions
• Historically Black Colleges and Universities (HBCUs)
• Tribally Controlled Colleges and Universities (TCCUs)
• Alaska Native and Native Hawaiian Serving Institutions
• Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

• Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
• Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

• Small Businesses
• For-Profit Organizations (Other than Small Businesses)

Governments

• State Governments
• County Governments
• City or Township Governments
• Special District Governments
• Indian/Native American Tribal Governments (Federally Recognized)
• Indian/Native American Tribal Governments (Other than Federally Recognized)
• Eligible Agencies of the Federal Government
• U.S. Territory or Possession

Other

• Independent School Districts
• Public Housing Authorities/Indian Housing Authorities
• Native American Tribal Organizations (other than Federally recognized tribal governments)
• Faith-based or Community-based Organizations
• Regional Organizations

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Applicant organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

• Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
• System for Award Management (SAM) Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  • NATO Commercial and Government Entity (NCAGE) Code Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
• eRA Commons - Applicants must have an active DUNS number to register in eRA Commons. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration , but all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
• Grants.gov Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101)

Section IV. Application and Submission Information

1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Letter of Intent

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

• Descriptive title of proposed activity
• Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
• Names of other key personnel
• Participating institution(s)
• Number and title of this funding opportunity

The letter of intent should be sent to:

Alfonso R. Latoni, PhD

Telephone: 984-287-3279

Email: [email protected]

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA. All instructions in the SF424 (R&R) Application Guide must be followed. All instructions in the SF424 (R&R) Application Guide must be followed. All instructions in the SF424 (R&R) Application Guide must be followed. All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed. All instructions in the SF424 (R&R) Application Guide must be followed. All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Research Strategy

Applications are expected to

• Demonstrate both strong scientific capabilities and strong collaboration, trust, and shared leadership and support with the proposed community partners/organizations.
• Provide evidence that the proposed community partners collaborated with the investigators to develop the research questions and goals for the project and include a ?plan or approach to ensure that the voices, ideas and concerns of the community partners are considered throughout the research project.
• Define the relevant community or communities of interest using a set of tangible and explicit criteria (e.g., a common interest, cultural or geographic identity, characteristic, exposure(s) or health condition).
• Identify the specific roles that individuals, organizations and advisory board members will play in the project and confirm that the time and effort proposed for community partners and organizational efforts reasonably reflect their involvement in the project.
• Describe proposed interactions and identify the specific translational approaches that are feasible, relevant, and culturally appropriate for that community and that will provide effective dissemination of findings, education, and/or trainings for all segments of the community.
• Explain why the research findings to be obtained in the project are vital to support the planned environmental public health action.
• Explain how their proposed public health strategy will lead to action with the community.

Additionally, applicants are encouraged to

• Include a management plan that describes the collaboration between the researchers and the community members. Describe how appropriate input of all partners will be achieved. The collaboration between the academic researchers and the community members or community organizations to be involved in the research should be established prior to submission of the application and the structure of the collaboration fully described in the management plan. Given the demographics of some communities, this may entail the involvement of more than one CBO, or more than one representative of a community, particularly if the community is identified through its exposure risk or poverty status and includes members of different racial and/or ethnic sub-populations.
• Include a summary plan for evaluating the project's processes and outcomes. The plan should describe the evaluation questions to be assessed; evaluation metrics that will be measured to answer evaluation questions; who, when, and how such data will be collected; and how data will be analyzed and incorporated into the ongoing study design.

Letters of Support:

• Demonstrate support for implementation of the project from the community, (e.g., the involvement of local or regional public health departments, public schools, churches or youth organizations, etc.)
• Demonstrate that community representatives/CBOs speak on behalf of the community and include letters of support from each organization to be involved in the research (e.g., representatives of an established public health department, CBO, church, and/or representatives of local youth organizations).

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide. All awardees will be expected to enter final materials developed as part of this project into the PEPH Resource Center.

The following modifications also apply:

• All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide. When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday , the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement .

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

In addition, for applications involving clinical trials:

A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed). Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

In addition, for applications involving clinical trials

Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?

Investigator(s)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Is there evidence of the investigators prior experience working with the specific subpopulations named in the application ?

Do the investigators speak the language(s) spoken in the affected communities or involved individuals to serve as translators for the project?

Do the investigators demonstrate awareness of specific cultural activities or beliefs that would affect or constrain the conduct of the project?

Do the investigators demonstrate the needed expertise for developing appropriate translation of findings back to the community or have they involved the appropriate disciplines to ensure culturally sensitive approaches?

In addition, for applications involving clinical trials

With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?

Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

In addition, for applications involving clinical trials

Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?

Approach

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project ? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

In addition, for applications involving clinical trials

Does the application adequately address the following, if applicable

Study Design

Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?

Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity?

Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?

Data Management and Statistical Analysis

Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?

Environment

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

In addition, for applications involving clinical trials

If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?

Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?

If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?

Study Timeline

Specific to applications involving clinical trials

Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?

Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?

Scientific progress

Does the project proposed include a balance between appropriate community engagement and demonstration that the scientific activities conducted will add to the knowledge base and not duplicate activities or approaches that simply confirm existing knowledge?

If applicable, is there evidence of the appropriate range of expertise for conducting a multidisciplinary study e.g., does the study include those with expertise in community-engagement, environmental health science and social science, at a minimum?

Will the project lead to new methodologies or approaches, or increase trust in research processes that will improve community-based research efforts?

Evidence of an established community-academic partnership ( at least one of the following criteria are required ):

Is there evidence that the partnership has existed for at least a year?

Have these partners conducted research together and/or published together? If this is a new partnership, does the community or professional/governmental organization have previous experience in research and have the infrastructure to handle federal funding?

Does the application include letters of support that specifically notes the proposed project?

Community partner roles and responsibilities

Does the application name community partners or organizations as Key Personnel?

Does the application include the CVs of community partners?

Protections for Human Subjects

For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

Inclusion of Women, Minorities, and Individuals Across the Lifespan

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

Not Applicable

Renewals

Not Applicable

Revisions

Not Applicable

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Applications from Foreign Organizations

Not Applicable

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).

Authentication of Key Biological and/or Chemical Resources:

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIEHS, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

• May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

• Will receive a written critique.

Appeals of initial peer review will not be accepted for applications submitted in response to this FOA. Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:

• Scientific and technical merit of the proposed project as determined by scientific peer review.
• Availability of funds.
• Relevance of the proposed project to program priorities.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information

1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.

Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.

ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain applicable clinical trials on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see https://grants.nih.gov/policy/clinical-trials/reporting/index.htm

Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the awardee must provide NIH copies of documents related to all major changes in the status of ongoing protocols. Data and Safety

Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).

Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person’s race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.

For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/index.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see https://www.hhs.gov/civil-rights/for-individuals/section-1557/index.htmlhttps://www.hhs.gov/civil-rights/for-providers/laws-regulations-guidance/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see https://www.hhs.gov/civil-rights/for-individuals/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.

Not Applicable

3. Reporting

When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement. A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 Award Term and Conditions for Recipient Integrity and Performance Matters.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)

Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: [email protected] (preferred method of contact)
Telephone: 301-945-7573

Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: [email protected]

Liam O Fallon
National Institute of Environmental Health Sciences (NIEHS)
Telephone: 984-287-3298
Email: [email protected]

Alfonso R. Latoni, Ph.D.
National Institute of Environmental Health Sciences
Telephone: 984-287-3279
Email: [email protected]

Jenny L. Greer
National Institute of Environmental Health Sciences (NIEHS)
Telephone: 984-287-3332
Email:[email protected]

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.